anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intervention will consist of engaging with the WW programme for 12 weeks, including weekly attendance at a local WW workshop and access to digital tools. Only the parent will take part in the WW intervention. No modifications will be made to the current WW programme to support child weight loss.
Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of "somewhat hard" (12-14 on the Borg scale). All exercises will be performed during hemodialysis.
Hypertrophic scars arise from aberrant wound healing and can lead to functional and aesthetic impairments. One of the common interventions for treating hypertrophic scars is fractional carbon dioxide (CO2) laser, which employs narrow laser beams to stimulate dermal collagen deposition. Recent studies and reports have suggested that combining laser therapy with other interventions such as botulinum toxin type A (BTX-A) and topical growth factors may enhance treatment outcomes. Here, we examine the efficacy and safety of a sequential combination of BTX-A, fractional CO2 laser, and topical growth factors, referred to as combined therapy, for treating hypertrophic scars compared with only using fractional CO2 laser and topical growth factors, referred to as monotherapy. Our retrospective study includes 128 patients with hypertrophic scars (56 underwent monotherapy and 72 underwent combined therapy), which were followed-up for up to 15 months after the initiation of treatment to collect demographic and clinical data. Our analysis showed that the combined therapy significantly outperformed monotherapy in improving Vancouver scar scale scores (P < 0.05) and in the reduction of scar thickness (P < 0.05), without increasing adverse complications. Repeated treatments further augmented the efficacy of the combined therapy. Subgroup analysis revealed that combined therapy was notably more effective in reducing Vancouver scar scale scores and scar thickness in early-stage scars compared to late-stage (P = 0.023 and P = 0.045, respectively). Our study suggests that including BTX-A treatment before fractional CO2 laser and topical growth factors offers superior efficacy in reducing hypertrophic scars. We encourage early intervention and repeated treatments for optimal treatment outcomes.
The invention provides for a a medical system comprising a control unit (102) and a medical appliance (104). The medical appliance is a body-worn medical appliance with a subcutaneous portion powered by a first battery. The medical appliance comprises a first wireless communication module and a sensor for measuring an analyte concentration. The control unit comprises a second wireless communication module and a second memory comprising an application partition (138) and a persistent partition (140). The application partition contains a medical application (142) and application data (144). The persistent partition contains archived data (146). The archived data comprises a copy of at least a portion of the application data. The medical application is configured for modifying the application data in the application partition and storing the portion of the application data comprised in the archived data in the persistent partition. The medical data entry comprises the analyte concentration, wherein execution of the medical appliance instructions cause the first processor to: record the analyte concentration using the monitoring system, generate a medical data entry at least partially using the analyte concentration, and transfer the medical data entry to the control unit using the wireless communication channel, wherein the application data comprises the medical data entry. The second memory further contains an operating system, wherein the operating system is operable for de-installing the medical application. The de-installation deletes the application data and preserves the archived data on the persistent partition.
The study is to measure the efficacy of new GDD that made with polymethyl methacrylate. The primary outcome is IOP reduction. The secondary outcome is glaucoma medication post surgery and complication that occurred during the follow up. The subjects are refractory glaucoma patients that need glaucoma drainage device implantation. The measurement are collected on first day, first month, third month, sixth month and twelve month. The IOP will be measured using GAT (Goldmann applanation tonometer), but if the subjects are not cooperative, they will be measured using i-care. On the follow up, the glaucoma medication needed will be noted and also for the complication and the need for other surgery, e.g. AC formation using viscoelastic, repair tube/plate exposure, cyclo photocoagulation, etc.
Diabetes is a risk factor for stroke; however, its impact on stroke progression at the genomic level is not well understood. To address this gap, we used transcriptome sequencing to explore the relationship between lncRNA and mRNA expression patterns and the reperfusion duration in the cortex of diabetically induced stroke mice. First, focal ischemia was induced in adult male ob/ob mice, which were then subjected to reperfusion periods of one, three, or seven days. Total RNA was extracted from the ischemic cortical tissue for RNA sequencing, and the resulting reads were aligned to the GRCm38 murine reference genome. A total of 672 mRNAs and 301 lncRNAs were identified as differentially expressed one day post-stroke, 1195 mRNAs and 66 lncRNAs at three days post-stroke, and 1069 mRNAs and 75 lncRNAs at seven days post-stroke. Stage-specific differentially expressed mRNAs were bioinformatically analyzed and found significantly enriched in processes such as apoptosis, angiogenesis, and lipid metabolism at one, three, and seven days post-stroke, respectively. Stage-specific DElncRNA-mRNA cis-regulatory relationships were constructed using these biological processes as examples, revealing the potential roles of four pairs of lncRNA-mRNAs (Gm39787-Lcn2, Gm46111-Drd2, D3300500i16Rik-Fosl1, and Gm41689-Egr1) in apoptosis. Additionally, Gm40237-Tie1 and Gm52352-Pdgfrb are associated with angiogenesis and lipid metabolism, respectively. In conclusion, our study demonstrated that lncRNA and mRNA expression in the cortex of transient focal ischemia-induced diabetic mice undergo extensive alterations, providing insights into complex molecular interactions underlying diabetic stroke.
The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
<P>PROBLEM TO BE SOLVED: To provide a mascara applicator capable of imparting a sufficient voluminous feeling to eyelashes.  <P>SOLUTION: This mascara cosmetic equipment 33 is provided with a container 31 housing a mascara agent and the mascara applicator 10 whose application part is immersed in the mascara agent. For the mascara agent, there is a non-Newtonian fluid one having the peak value of tanδ at the angular velocity of 1-10 rad/sec. The application part of the mascara applicator 10 is constituted of an application part shaft and comb teeth. The comb teeth 20 are constituted of an elastomer whose Shore hardness (A) is 45-85, and an annular piece and a projection piece are integrally formed.  <P>COPYRIGHT: (C)2007,JPO&INPIT
This study is observational in nature, in that the participants in the control group will be treated according to treatment as usual and best judgment of the treating clinician. The participants in the experimental group will be treated with adjunctive information provided by the PEER Interactive Report. It is a controlled study in that the schedule of visits, procedures and measurements will be defined by the protocol in order to provide consistent data for both the control and experimental groups.

Participants will be blinded as to presence/use of the PEER Interactive Report and will provide the primary efficacy outcome evaluation. All participants will be randomized into a control or experimental group. All participants will receive a quantitative electroencephalogram (QEEG). For those participants in the experimental group, the research staff will receive an Outcome Report from PEER Interactive. The clinician in the experimental group will use the PEER Interactive Report in the medication prescription process. For the control group, the research staff will not receive an Outcome Report. Outcome Reports for the control group will be sequestered for post-hoc analysis.

The research staff will incorporate the information provided by the Outcome Report from PEER Interactive in their prescription decisions. PEER Interactive provides adjunctive information to assist the treating clinician in the clinical decision process. For the experimental group the research staff is expected to follow the guidance of the subject's PEER Outcome Report as regards to the participant's responsiveness to the on-label medications noted in the Report. Although the study staff is strongly encouraged to use the guidance in the medication decision, prescription of medication is a clinical decision and will be made by the research staff
Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
The invention discloses a preparation method of a recombinant yeast with surface display of prawn white spot syndrome virus VP28, and the recombinant yeast with surface display of VP28 is obtained by performing recombination of a yeast surface display carrier pYD1 with a prawn white spot syndrome virus protein VP28 gene to construct a recombinant plasmid with fusion expression, and transforming saccharomyces cerevisiae EBY100. The invention is characterized in that the recombinant yeast EBY100 containing the prawn white spot syndrome virus protein VP28 gene has VP28 on the surface. Another purpose of the invention is to provide an application of a recombinant yeast live vaccine with surface display of the prawn white spot syndrome virus VP28 in culture of shell-fish animals. The prepared recombinant yeast can be used as an oral vaccine for prawn immunization, and can be used for protecting prawns from being infected by prawn white spot syndrome viruses. The advantages of the gene engineering live vaccine in the invention are that the used saccharomyces cerevisiae is safe; the culture method is simple and practical, and convenient for large-scale production. With respect to other vaccines, the displayed VP28 protein is easy to be recognized by the immune system, and the displayed VP28 protein has good stability.
Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
Muscarinic symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions, and bradycardia) may appear with overdosage of neostigmine methylsulfate injection (cholinergic crisis), but may be managed by the use of additional atropine or glycopyrrolate. The possibility of iatrogenic overdose can be lessened by carefully monitoring the muscle twitch response to peripheral nerve stimulation. Should overdosage occur, ventilation should be supported by artificial means until the adequacy of spontaneous respiration is assured, and cardiac function should be monitored.

Overdosage of neostigmine methylsulfate injection can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. Myasthenic crisis, due to an increase in the severity of the disease, is also accompanied by extreme muscle weakness and may be difficult to distinguish from cholinergic crisis on a symptomatic basis. However, such differentiation is extremely important because increases in the dose of neostigmine methylsulfate injection or other drugs in this class, in the presence of cholinergic crisis or of a refractory or "insensitive" state, could have grave consequences. The two types of crises may be differentiated by the use of edrophonium chloride as well as by clinical judgment.

Treatment of the two conditions differs radically. Whereas the presence of myasthenic crisis requires more intensive anticholinesterase therapy, cholinergic crisis calls for the prompt withdrawal of all drugs of this type. The immediate use of atropine in cholinergic crisis is also recommended. Atropine may also be used to lessen gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.
The following adverse reactions have been identified with the use of intravenous pertuzumab and trastuzumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  * Glomerulopathy
  * Immune thrombocytopenia
  * Tumor lysis syndrome (TLS): Patients with significant tumor burden (e.g. bulky metastases) may be at a higher risk. Patients could present with hyperuricemia, hyperphosphatemia, and acute renal failure which may represent possible TLS. Providers should consider additional monitoring and/or treatment as clinically indicated.
Parents of children with ADHD who are randomized in Treatment Group will first take part in a pre-tested 4-session MFNT intervention programme. The parents will participate in lectures, group discussions, video demonstrations, and in-group exercises offered in these four mentored sessions, while their children will attend the second and fourth sessions.
TOPIC IMPORTANCE: Death is common in the ICU and often occurs after a decision to withhold or withdraw life-sustaining therapies. Care of the dying is a core skill for ICU clinicians, requiring expert communication, primarily with family of critically ill patients.
REVIEW FINDINGS: Limited high-quality evidence supports specific practices related to the care of dying patients in the ICU; thus, many of the recommendations that exist are based on expert opinion. Value exists in sharing a practical approach to caring for patients during the dying process, including topics to be addressed with family members, rationales for recommended care, and strategies for implementing comfort measures only. Through dedicated preparation and planning, clinicians can help family members navigate this intense experience.
SUMMARY: After a decision had been made to discontinue life-sustaining therapies, family members need to be given a clear description of comfort measures only and provided with additional detail about what it entails, including therapies or interventions to be discontinued, monitoring during the dying process, and common features of the dying process. Order sets can be a valuable resource for ensuring that adequate analgesia and sedation are available and the care plan is enacted properly. To achieve a good death for patients, a collaborative effort among members of the care team is essential.
PURPOSE: To determine the correlation and classification consistency of femoral version measurements between magnetic resonance (MR) and computed tomography (CT) using 4 commonly used measurement methods.
METHODS: A retrospective study was performed on patients with femoroacetabular impingement (FAI) who received preoperative CT and MR imaging assessment of the surgical hip and ipsilateral distal femur. Femoral version was measured using the Murphy method, the oblique method, the Reikerås method, and the Lee method. Intra- and inter-rater agreements were calculated. Linear regression and Bland-Altman analysis were performed for measurements using different imaging modalities and measurement methods. Femoral version measurements within the lower quartile, the middle 2 quartiles, and the upper quartile were classified into different groups based on their percentile within the sample population. Classification consistency rates between modalities and methods were calculated and compared.
RESULTS: Fifty-three patients (39.4 ± 9.1 years; 32 female) were included for analysis. Intra- and inter-rater reliability were high for all modalities and methods (intrarater intraclass correlation coefficient [ICC] range, 0.963-0.993; inter-rater ICC range, 0.871-0.960). MR- and CT-based femoral version measurements showed strong correlations for all methods, with the Lee method demonstrating the strongest association (r = 0.904), while the oblique method exhibited the lowest correlation (r = 0.684) (all P < .001). MR-based measurements were smaller than CT-based measurements, with mean differences ranging from 4.5° to 10.3°. Classification consistency between MR and CT ranged from 51% to 74%, whereas the consistency between different measurement methods ranged from 68% to 85%.
CONCLUSIONS: While strong correlations were observed between MR- and CT-based femoral version measurements, MR-based measurements were significantly smaller than their CT counterparts. Classification consistency between the modalities was moderate to high. Measurements between different methods showed strong correlations with high consistency rates.
LEVEL OF EVIDENCE: Level III, retrospective case series.
All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction . After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
Fatty liver grafts are susceptible to ischemia reperfusion injury (IRI), increasing the risk of biliary complications after liver transplantation (LT). Ferroptosis, a newly recognized programmed cell death, is expected to be a novel therapeutic target for IRI. We investigated whether exosomes derived from heme oxygenase 1-modified bone marrow mesenchymal stem cells (HExos) relieve ferroptosis and protect biliary tracts from IRI in a rat fatty liver transplantation model. Rats were fed with a methionine choline deficient (MCD) diet for 2 weeks to induce severe hepatic steatosis. Steatotic grafts were implanted and HExos were administered after liver transplantation. A series of functional assays and pathological analysis were performed to assess ferroptosis and biliary IRI. The HExos attenuated IRI following liver transplantation, as demonstrated by less ferroptosis, improved liver function, less Kupffer and T cell activation, and less long-term biliary fibrosis. MicroRNA (miR)-204-5p delivered by HExos negatively regulated ferroptosis by targeting a key pro-ferroptosis enzyme, ACSL4. Ferroptosis contributes to biliary IRI in fatty liver transplantation. HExos protect steatotic grafts by inhibiting ferroptosis, and may become a promising strategy to prevent biliary IRI and expand the donor pool.
Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
PURPOSE:To obtain a processed crude drug by immersing fruit of Lycium chinense or Nephelium longanum in an alcohol and sweetening the extract. CONSTITUTION:Crude drug selected from Lycium chinense belonging to the family So lanaceae and Nephelium longanum belonging to the family Sapindaceae is immersed in an alcohol having an alcohol concentration of 25-35% for about 30-80 days. The immersion liquid is sweetened with a sugar such as sucrose and fructose, honey, natural sweetener, etc. The alcohol immersion treatment and the sweetening treatment are carried out at the same time or in arbitrary order. Since these crude drugs have poor digestibility as it is to retard the absorption of the active components, the drugs are immersed in alcohol and used as a medical liquor. The medical liquor prepared from Lycium chinense and Nephewium longanum has bitter taste and, accordingly, the liquor is sweetened and used as it is or as a processed herb drug prepared by mixing the liquor into a food.
Prepare each dose immediately prior to administration.

Measure 1/3 cup of water. Pour half of the water into a glass, then add the packet(s) of Veltassa and stir. Add the remaining half of the water and stir thoroughly. The powder will not dissolve and the mixture will look cloudy. Add more water to the mixture as needed for desired consistency.

Drink the mixture immediately. If powder remains in the glass after drinking, add more water, stir and drink immediately. Repeat as needed to ensure the entire dose is administered.

Other beverages or soft foods (e.g., apple sauce, yogurt, pudding) can be used instead of water to prepare the mixture by following the same steps as described above. A minimum volume of 45 mL (3 tablespoons) can be used to prepare doses up to and including 4 grams patiromer.

The potassium content of liquids or soft foods used to prepare the mixture should be considered as part of the dietary recommendations on potassium intake for each individual patient.
PCT No. PCT/GB96/00312 Sec. 371 Date Aug. 13, 1997 Sec. 102(e) Date Aug. 13, 1997 PCT Filed Feb. 14, 1996 PCT Pub. No. WO96/25502 PCT Pub. Date Aug. 22, 1996There is provided a novel adenylate cyclase enzyme, the nucleotide sequence of which is set out in SEQ ID No 1. The activity of the adenylate cyclase is uniquely regulated by calcineurin, a protein phosphatase. The calcineurin binding site has been identified at amino acids 503 to 610 of the novel adenylate cyclase. Regulation of the novel adenylate cyclase may be useful in treating certain disorders. Suitable regulators include agents which bind to the 503-610 amino acid site and include calcineurin, its activators, inhibitors and competitors and antibodies specific to that site. Specific disorders include neurological disorders such as Parkinsons' disease, cardiovascular disorders such as angina pectoris and tumors, especially ovarian tumors.
Bipolar disorder is a mental disease characterized by mood dysregulation and arises from manic, depressive or mixed episodes. During these episodes, formal thought disorders are observed, associated to emotional perturbation, behaviour troubles and some psychotic symptoms. During mania, the type of thought disorders observed are derailment, flight of ideas, with an increase in the amount of spontaneous speech and loss of goal. These observations of the patient's speech and language behaviour probably result from an underlying disturbance in semantic networks dealing with semantic associations. These networks have been studied extensively in schizophrenia but remain unknown in bipolar disorder. In this context, the aim of our study will be to have a better comprehension of formal thought disorders in bipolar disorder by cognitive exploration of semantic activation and inhibition.